Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases

2020 ◽  
pp. 327-335
Author(s):  
Virginia Cappagli ◽  
Valeria Bottici ◽  
Rossella Elisei
2000 ◽  
Vol 7 (3) ◽  
pp. 253-261 ◽  
Author(s):  
Gregory W. Randolph ◽  
Dipti Maniar

Medullary thyroid cancer (MTC) is a distinct C-cell tumor of the thyroid. We review the oncogenesis and management of both sporadic tumors and those tumors arising as part of specific inherited syndromes. The RET proto-oncogene plays a role in the development of inherited forms of MTC and has become important in the clinical management of patients and their families. The recognition of the high rate of regional nodal involvement has led to lymphadenectomy being strongly considered for patients undergoing thyroidectomy for MTC.


2014 ◽  
Vol 82 (6) ◽  
pp. 892-899 ◽  
Author(s):  
Cristina Romei ◽  
Alessia Tacito ◽  
Eleonora Molinaro ◽  
Laura Agate ◽  
Valeria Bottici ◽  
...  

2021 ◽  
Vol 66 (1) ◽  
pp. 79-84
Author(s):  
I Pimonova ◽  
V. Krylov ◽  
P Isaev ◽  
T. Kochetova ◽  
E Borodavina

The article reviews domestic and foreign literature on the use of radiation therapy in the treatment of medullary thyroid cancer. The possibilities of various radiation methods in the treatment of patients with distant metastases are shown. In addition to classical types of remote irradiation, data are presented on the possibilities of radionuclide therapy (peptide-receptor therapy with somatostatin analogs and radionuclide therapy with osteotropic drugs for bone metastases). Methods of combined therapy with the use of osteomodifying agents, targeted drugs and other methods are described, which make it possible to increase the effectiveness of treatment of patients with medullary thyroid cancer with bone metastases.


2019 ◽  
Vol 9 (3) ◽  
pp. 38-48
Author(s):  
А. М. Mudunov ◽  
Yu. V. Alymov ◽  
I. S. Romanov ◽  
S. О. Podvyaznikov ◽  
А. V. Ignatova

Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyroid malignancies. MTC is usually detected at early stages; however, approximately 10–15 % of patients are diagnosed with locally advanced MTC and distant metastases. Treatment of such patients is challenging due to biological characteristics of the disease and very few effective treatment approaches available. The investigation of mechanisms of carcinogenesis, as well as advances in pharmacology, allowed the development of a new group of targeted drugs, namely tyrosine kinases, which efficacy against progressive unresectable locally advanced or metastatic MTC has been demonstrated in multiple clinical trials. Vandetanib has been registered for MTC treatment in the Russian Federation. MTC is very rare, thus, each case of vandetanib use for its treatment is particularly interesting. Moreover, since the approval of this drug in 2011 by the U. S. Food and Drug Administration (FDA), new data on the clinical use of vandetanib have been accumulated. Importantly, clinical trials are usually well designed and conducted in near-ideal conditions, whereas the real conditions can be different and patients may have individual characteristics. Therefore, the aim of this study was to update the information on the efficacy and safety of vandetanib by retrospective analysis of available publications and to report a case of MTC treated with vandetanib.


Author(s):  
Andreas Machens ◽  
Kerstin Lorenz ◽  
Frank Weber ◽  
Henning Dralle

Abstract Context Risk factors of lymph node and distant metastases have rarely been analyzed in hereditary and sporadic medullary thyroid cancer (MTC) using large genetic-clinical data sets. Objective This comprehensive investigation aimed to explore risk factors of lymph node and distant metastases and interdependencies between age at thyroidectomy, primary tumor size, lymph node metastasis and distant metastasis in patients with hereditary and sporadic MTC. Methods Comparative analyses of risk factors of metastasis, stratified by hereditary MTC (four mutational risk categories) and sporadic MTC. Results There were 1115 patients with hereditary MTC (307 patients) or sporadic MTC (808 patients). Age at thyroidectomy increased proportionately from 12.2, 22.7, 34.3, and 49.8 years for patients with decreasing mutational risk, as compared to 52.1 years for patients with sporadic MTC. Metastatic primary tumors overall were 10.7–19.4 mm larger in node-positive patients and 15.9–19.3 mm larger in distant metastatic patients at thyroidectomy than nonmetastatic tumors. Distant metastases were noted in 13–50% of node-positive vs. 0% of node-negative hereditary MTC, and in 23.5% of node-positive vs. 1.7% of node-negative sporadic MTC. In multivariable logistic regression analysis for sporadic MTC, lymph node metastasis contributed to distant metastasis (odds ratio 12.4) more than primary tumor size (odds ratios of 7.8, 5.5 and 2.4 for tumors measuring >60, 41–60 and 21–40 mm). Conclusions When thyroidectomy is performed before lymph node metastases have developed, distant metastases are exceptional, both in patients with hereditary MTC, irrespective of the level of mutational risk, and patients with sporadic MTC.


Head & Neck ◽  
2021 ◽  
Vol 43 (11) ◽  
pp. 3386-3392
Author(s):  
Shi‐Min Zhuang ◽  
Liang‐En Xie ◽  
Feng Pang ◽  
Qian‐Yi Zhong ◽  
Xiao‐Mei Sun ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
D. Pach ◽  
A. Sowa-Staszczak ◽  
A. Jabrocka-Hybel ◽  
A. Stefańska ◽  
M. Tomaszuk ◽  
...  

Introduction. Epidemiological studies on medullary thyroid cancer (MTC) have shown that neither a change in stage at diagnosis nor improvement in survival has occurred during the past 30 years. In patients with detectable serum calcitonin and no clinically apparent disease, a careful search for local recurrence, and nodal or distant metastases, should be performed. Conventional imaging modalities will not show any disease until basal serum calcitonin is at least 150 pg/mL. The objective of the study was to present the first experience with labelled glucagon-like peptide-1 (GLP-1) analogue [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 in the visualisation of MTC in humans.Material and Method. Four patients aged 22–74 years (two with sporadic and two with MEN2 syndrome-related disseminated MTC) were enrolled in the study. In all patients, GLP-1 receptor imaging was performed.Results. High-quality images were obtained in all patients. All previously known MTC lesions have been confirmed in GLP-1 scintigraphy. Moreover, one additional liver lesion was detected in sporadic MTC male patient.Conclusions. GLP-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 is able to detect MTC lesions. GLP-1 scintigraphy can serve as a confirmatory test in MTC patients, in whom other imaging procedures are inconsistent.


2020 ◽  
Vol 7 (1) ◽  
pp. IJE27
Author(s):  
Rui Zheng-Pywell ◽  
Anish Jacob Cherian ◽  
Macie Enman ◽  
Herbert Chen ◽  
Deepak Abraham

Aim: This study investigates if serum calcitonin or carcinoembryonic antigen (CEA) levels can differentiate between locoregional and metastatic medullary thyroid cancer. Methods: A single institution retrospective analysis was performed on 88 patients with medullary thyroid cancer between 2008 and 2014. Results: In M0disease, calcitonin (p < 0.001) and CEA (p = 0.003) significantly decreased postoperatively. Not only was the correlation significant between calcitonin and CEA preoperatively (r = 0.72; p < 0.001) and postoperatively (r = 0.68; p < 0.001), calcitonin could extrapolate CEA levels (p < 0.001). These findings were statistically insignificant in metastatic disease. Conclusion: Independently, calcitonin and CEA fail to differentiate between locoregional and metastatic disease. Both are essential for prognostication: loss of concordance is suspicious for metastatic disease. Hence, discordant CEA and calcitonin levels should be an indication to pursue additional imaging.


Sign in / Sign up

Export Citation Format

Share Document